Sökning: (WFRF:(Blimark Cecilie)) > Secondary immunodef...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03404naa a2200457 4500 | |
001 | oai:gup.ub.gu.se/247741 | |
003 | SwePub | |
008 | 240528s2016 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:134705118 | |
024 | 7 | a https://gup.ub.gu.se/publication/2477412 URI |
024 | 7 | a https://doi.org/10.1002/hon.23232 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1347051182 URI |
040 | a (SwePub)gud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Friman, Vanda,d 1952u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xfriva |
245 | 1 0 | a Secondary immunodeficiency in lymphoproliferative malignancies |
264 | c 2016-07-12 | |
264 | 1 | b Wiley,c 2016 |
520 | a Secondary immunodeficiencies occur as a consequence of various diseases, including hematological malignancies, and the use of pharmacological therapies, such as immunosuppressive, anti-inflammatory, and biological drugs. Infections are the main cause of morbidity and mortality in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients. Recent advances in treatment have prolonged the duration of remission and the time between relapse phases in MM and CLL patients. However, managing multiple relapses and the use of salvage therapies can lead to cumulative immunosuppression and a higher risk of infections. The pathogenesis of immune deficiency secondary to lymphoproliferative malignancy is multifactorial including disease- and treatment-related factors. Supportive treatment, including early vaccination, anti-infective prophylaxis, and replacement immunoglobulin, plays a key role in preventing infections in MM and CLL. This article provides an overview of the basic immunology necessary to understand the pathogenesis of secondary immunodeficiency and the infectious complications in MM and CLL. We also discuss the evidence supporting the role of prophylactic replacement immunoglobulin treatment in patients with antibody failure secondary to MM and CLL and the indications for its use. Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a chronic lymphocytic leukemia | |
653 | a infections | |
653 | a multiple myeloma | |
653 | a prophylaxis | |
653 | a replacement immunoglobulin | |
653 | a secondary immunodeficiencies | |
653 | a supportive therapy | |
700 | 1 | a Winqvist, O.u Karolinska Institutet4 aut |
700 | 1 | a Blimark, Cecilie4 aut |
700 | 1 | a Langerbeins, P.4 aut |
700 | 1 | a Chapel, H.4 aut |
700 | 1 | a Dhalla, F.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för biomedicin, avdelningen för infektionssjukdomar4 org |
773 | 0 | t Hematological Oncologyd : Wileyg 34:3, s. 121-132q 34:3<121-132x 0278-0232x 1099-1069 |
856 | 4 8 | u https://gup.ub.gu.se/publication/247741 |
856 | 4 8 | u https://doi.org/10.1002/hon.2323 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:134705118 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.